mdlinx mdlinx
Latest (118) Full Text Articles (6313) Focus on Bone Article Summary

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomized trials
The Lancet, 11/11/2011

Breast Cancer Trialists' Collaborative Group et al. – After breast-conserving surgery, radiotherapy to the conserved breast halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth. These proportional benefits vary little between different groups of women. The absolute benefits from radiotherapy vary substantially according to the characteristics of the patient and they can be predicted at the time when treatment decisions need to be made.

Methods

  • Meta-analysis of individual patient data for 10,801 women in 17 randomised trials of radiotherapy versus no radiotherapy after breast-conserving surgery
  • 8337 of whom had pathologically confirmed node-negative (pN0) or node-positive (pN+) disease

Results

  • Radiotherapy reduced 10-year risk of any (ie, locoregional or distant) first recurrence from 35·0% to 19·3% (absolute reduction 15·7%, 95% CI 13·7—17·7, 2p<0·00001) and reduced 15-year risk of breast cancer death from 25·2% to 21·4% (absolute reduction 3·8%, 1·6—6·0, 2p=0·00005)
  • In women with pN0 disease (n=7287), radiotherapy reduced these risks from 31·0% to 15·6% (absolute recurrence reduction 15·4%, 13·2—17·6, 2p<0·00001) and from 20·5% to 17·2% (absolute mortality reduction 3·3%, 0·8—5·8, 2p=0·005)
  • In women with pN0 disease, absolute recurrence reduction varied according to age, grade, oestrogen-receptor status, tamoxifen use, and extent of surgery, and these characteristics were used to predict large (?20%), intermediate (10—19%), or lower (<10%) absolute reductions in the 10-year recurrence risk
  • Absolute reductions in 15-year risk of breast cancer death in these three prediction categories were 7·8% (95% CI 3·1—12·5), 1·1% (—2·0 to 4·2), and 0·1% (—7·5 to 7·7) respectively (trend in absolute mortality reduction 2p=0·03)
  • In the few women with pN+ disease (n=1050), radiotherapy reduced the 10-year recurrence risk from 63·7% to 42·5% (absolute reduction 21·2%, 95% CI 14·5—27·9, 2p<0·00001) and the 15-year risk of breast cancer death from 51·3% to 42·8% (absolute reduction 8·5%, 1·8—15·2, 2p=0·01)
  • About one breast cancer death was avoided by year 15 for every 4 recurrences avoided by year 10, and mortality reduction did not differ significantly from overall relationship in any of the 3 prediction categories for pN0 disease or for pN+ disease

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

1 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013    Clinical Article

2 R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi Journal of Clinical Oncology, April 1, 2013    Clinical Article

3 Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 Mayo Clinic Proceedings, April 2, 2013    Clinical Guideline

4 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013    Clinical Article

5 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma Neuro-Oncology, April 9, 2013    Clinical Article

6 Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study Journal of the National Cancer Institute, April 4, 2013    Clinical Article

7 Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments Full Text BMC Cancer, April 3, 2013    Free full text    Clinical Article

8 Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial Journal of Clinical Oncology, February 11, 2013    Clinical Article

9 Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial The Lancet Oncology, March 12, 2013    Clinical Article

10 Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Annals of Oncology, April 1, 2013    Clinical Article

11 High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma European Journal of Cancer, April 5, 2013    Clinical Article

12 Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial The Lancet Oncology, April 12, 2013    Clinical Article

13 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013    Clinical Article

14 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 11, 2013    Clinical Article

15 Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer Cancer, April 10, 2013    Clinical Article

16 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial The Lancet Oncology, February 15, 2013    Clinical Article

17 Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab: Results of the randomised GeparQuinto study (GBG 44) European Journal of Cancer, April 5, 2013    Clinical Article

18 Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Annals of Oncology, April 4, 2013

19 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013

20 R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma British Journal of Haematology, March 1, 2013    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close